乌司奴单抗与维得利珠单抗在抗TNF难治性克罗恩病中的疗效比较
这项多中心回顾性观察性队列研究纳入239例抗TNF难治或不耐受的克罗恩病患者,比较乌司奴单抗与维得利珠单抗的疗效与安全性。第48周时,乌司奴单抗组的临床缓解率和治疗持续率均显著高于维得利珠单抗组,但无激素临床缓解率两组无显著差异。
要点
- 抗TNF难治性CD患者中,乌司奴单抗第48周临床缓解率优于维得利珠单抗。
- 乌司奴单抗治疗持续率也显著高于维得利珠单抗。
- 联合治疗与第48周更高的临床缓解率相关。
核心结论
- 在抗TNF难治或不耐受的CD患者中,随访48周时乌司奴单抗与更高的临床缓解率和治疗持续率相关。
- 两药的无激素临床缓解率无显著差异。
研究设计与样本
- 多中心回顾性观察性队列研究,纳入2014年5月至2018年8月期间连续启动维得利珠单抗或乌司奴单抗的抗TNF难治或不耐受CD患者。
- 共纳入239例患者,其中107例接受乌司奴单抗,132例接受维得利珠单抗;采用意向性治疗分析和倾向评分加权比较。
主要发现
- 第48周,乌司奴单抗组临床缓解率为54.4%,维得利珠单抗组为38.3%(OR=1.92,95%CI [1.09-3.39])。
- 第48周,乌司奴单抗组治疗持续率为71.5%,维得利珠单抗组为49.7%(OR=2.54,95%CI [1.40-4.62])。
- 第48周无激素临床缓解率两组分别为44.7%和34.0%,差异无统计学意义(OR=1.57,95%CI [0.88-2.79])。
- 亚组分析显示,回肠病变患者中乌司奴单抗第48周临床缓解率更高(OR=3.49,95%CI [1.33-9.17])。
- 穿透性行为患者中乌司奴单抗第48周临床缓解率更高(OR=6.58,95%CI [1.91-22.68])。
关键数值与推荐
- 无论治疗分组,启动时联合治疗与第48周更高的临床缓解率相关(OR=1.93,95%CI [1.09-3.43])。
临床怎么用
- 对于抗TNF难治或不耐受的CD患者,乌司奴单抗可作为优先考虑的选项之一,尤其回肠病变或穿透性行为患者。
- 启动生物制剂时联合治疗可能提高第48周临床缓解率。
局限性
- 回顾性观察性设计,非头对头随机对照试验。
- 样本量有限,亚组分析结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no head-to-head trial comparing ustekinumab and vedolizumab in patients with Crohn's disease (CD) refractory to anti-tumour necrosis factor (anti-TNF). AIM: To compare the effectiveness and safety of ustekinumab and vedolizumab in patients with CD refractory to anti-TNF in a multicentre retrospective observational cohort. METHODS: All consecutive patients with CD refractory or intolerant to anti-TNF who initiated either vedolizumab or ustekinumab were included between May 2014 and August 2018. Clinical remission, steroid-free clinical remission (SFCR) and treatment persistence were assessed at week 48 with intention-to-treat analysis and propensity scores weighted comparison. RESULTS: A total of 239 patients were included, 107 received ustekinumab and 132 received vedolizumab. At week 48, ustekinumab was associated with a higher clinical remission rate (54.4% vs 38.3%; odds ratios, OR = 1.92, 95% CI [1.09-3.39]) and treatment persistence (71.5% vs 49.7%; OR = 2.54, 95% CI [1.40-4.62]) than vedolizumab. The rate of SFCR did not differ significantly between ustekinumab and vedolizumab (44.7% vs 34.0%; OR = 1.57, 95% CI [0.88-2.79]). Subgroup analyses showed that ustekinumab was associated with a higher clinical remission rates at week 48 in patients with ileal location (OR = 3.49, 95% CI [1.33-9.17) and penetrating behaviour (OR = 6.58, 95% CI [1.91-22.68]). Regardless of the treatment group, combination therapy at initiation was associated with a higher clinical remission rate at week 48 (OR = 1.93, 95% CI [1.09-3.43]). CONCLUSION: This study suggests that ustekinumab is associated with a higher rate of clinical remission and treatment persistence than vedolizumab after 48 weeks of follow-up, in patients with CD refractory or intolerant to anti-TNF. The rate of SFCR was not significantly different.
引用
- Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020. PMID: 32249966. doi:10.1111/apt.15706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。